ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa. We show 45 historical shares outstanding datapoints in our CCXI shares outstanding history coverage, used to compute CCXI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CCXI market cap history over the course of time is important for investors
interested in comparing CCXI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CCXI versus a peer is one thing; comparing
CCXI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CCXI can fluctuate over the course of history.
With this page we aim to empower investors researching CCXI by allowing them to research the CCXI market cap history. |
Free CCXI Email Alerts:
Video: The Importance of Market Cap
